Condition: Invasive Breast Cancer · Sponsor: Istituti Clinici Scientifici Maugeri SpA
The aim of this study is to establish patient-derived organoid (PDO) and tumor tissue cultures from breast cancer patients, in order to create personalized, accurate, and reliable preclinical models capable of providing information on the diverse biomolecular portraits of breast cancer. These models may also be used to predict the achievement of pathological complete response after neoadjuvant chemotherapy (NAC) treatment, study the biological, molecular, genetic, and microenvironmental characteristics of each tumor, and isolate tumor-derived extracellular vesicles from the PDOs and tissues and analyze them as potential biomarkers of response to NAC.
This description comes directly from the study's public registry record.
Fabio CorsI · +390382592272 · fabio.corsi@icsmaugeri.it
Marta Truffi · +390382592219 · marta.truffi@icsmaugeri.it
Always discuss trial participation with your own doctor first.
| Istituti Clinici Scientifici Maugeri | Pavia, PV, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07260188